REPL NASDAQ
Replimune Group, Inc.
1W: +5.9%
1M: +130.0%
3M: -39.6%
YTD: -41.4%
1Y: -43.2%
3Y: -71.8%
5Y: -85.1%
$4.91
-0.31 (-5.94%)
Weekly Expected Move ±31.0%
$2
$4
$5
$7
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (63)
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
FDA head Makary defends drug application rejections amid criticism
What's Going On With Replimune Stock On Tuesday?
FDA said to have named Katherine Szarama as acting CBER chief
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
12 Health Care Stocks Moving In Thursday's Intraday Session
Traders Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)
RFK Jr. says no hand in rejecting Replimune’s lead asset
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of “Reduce” from Brokerages
Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision
FDA Rejection Sparks Questions On Replimune Drug Approval Path
12 Health Care Stocks Moving In Monday's Intraday Session
Crude Oil Gains 5%; Fastenal Shares Fall After Q1 Earnings
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
Street sours on Replimune as stock hits all-time low on melanoma drug rejection
Biggest stock movers Monday: REPL, GS, LEG and more
Dow Dips Over 350 Points; Goldman Sachs Posts Upbeat Earnings
This NXP Semiconductors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
12 Health Care Stocks Moving In Monday's Pre-Market Session
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Replimune Group, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Biggest stock movers Monday: REPL, BKR, and more
Replimune shares extend losses, tumble 56% after FDA rejects melanoma drug RP1
Replimune Group (NASDAQ:REPL) Stock Price Up 6.2% – Here’s Why
Replimune plans layoffs as FDA rejects cancer drug
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
FDA Again Rejects Replimune Skin Cancer Therapy, Says Evidence Falls Short
12 Health Care Stocks Moving In Friday's Intraday Session
Replimune under pressure as FDA rejects lead asset again
What's Going On With Replimune Stock Friday?
Stock Traders Purchase Large Volume of Replimune Group Put Options (NASDAQ:REPL)
FDA Review Looms As Replimune Faces Weak Technical Setup
12 Health Care Stocks Moving In Wednesday's Intraday Session
Replimune Group (NASDAQ:REPL) Trading Down 6.7% on Insider Selling
Replimune Group (NASDAQ:REPL) Insider Christopher Sarchi Sells 6,500 Shares of Stock
Replimune Group (NASDAQ:REPL) Shares Up 7.2% – Here’s Why
Catalyst Watch: OPEC meeting, FedEx talks freight, inflation reads, and SpaceX IPO buzz
Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Hold” by Analysts
CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Biotech firm stocks rise on FDA vaccine head’s exit
Mirum Completes Enrollment & Screening in Liver Disease Studies
Bayer Advances Roundup Settlement With Missouri Court Approval
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of “Hold” by Analysts
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
SG Americas Securities LLC Increases Stake in Replimune Group, Inc. $REPL
Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
Squarepoint Ops LLC Grows Stock Position in Replimune Group, Inc. $REPL
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of “Moderate Buy” by Brokerages